NewStem
Jerusalem
About NewStem
NewStem is a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. NewStem's technology can predict patients' resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: Seed
- Last round: Seed (Sep 2021)
- Website: newstem.com
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/newstem-93156 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.